- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01512953
Effect of Proton Pump Inhibitor on Residual Platelet Reactivity After Clopidogrel in Homogenous Genetic Strata (GENIOUS)
Randomized Comparison of PPI Versus no PPI on Top of Standard Dose Clopidogrel Therapy in Patients Stratified Based on CYC2C19 Activity Via a Genetic Point of Care System.
Study Overview
Detailed Description
In managing patients who undergo percutaneous coronary intervention (PCI), rapid and predictable platelet inhibition for all patients is an important therapeutic goal. Determining the optimal dose of antiplatelet therapy to achieve this goal has been hampered by considerable interpatient variability in response to clopidogrel, which largely reflects gene polymorphism. Most of the evidence is centred around cytochrome 450 2C19.
A substudy of TRITON TIMI 38 has recently shown that among persons treated with clopidogrel, carriers of a reduced-function CYP2C19 allele had significantly lower levels of the active metabolite of clopidogrel, diminished platelet inhibition, and a higher rate of major adverse cardiovascular events, including stent thrombosis, than did noncarriers (N Engl J Med 2009;360:354-62). As a contrary, common functional CYP genetic variants do not affect active drug metabolite levels, inhibition of platelet aggregation, or clinical cardiovascular event rates in persons treated with prasugrel (Circulation. 2009 May 19;119(19):2553-60).
More recently, it has been shown that CYP2C19*17 carrier status is significantly associated with enhanced response to clopidogrel and an increased risk of bleeding. (Circulation. 2010;121:512-518). Whether CYP2C19*17 carrier status enhances response to prasugrel is unknown.
Attention has also been placed on a potential interaction observed between clopidogrel and the widely used proton pump inhibitors (PPIs).
The CYP2C19 isoform is the key enzyme in the metabolism of many of the PPIs, which are also inhibitors of the CYP2C19 isoenzyme in varying degrees. This is important because the antiplatelet effects of clopidogrel rely, to a degree, upon CYP2C19 activity. However, the recent COGENT study and sub-analysis of the TRITON-TIMI 38 have both apparently mitigated this concern. Nevertheless, it is unknown whether PPI can father blunt response to clopidogrel especially in patients carrying the loss of function 2C19 allele.
A recent review paper (Aliment Pharmacol Ther 31, 810-823) included 23 studies covering 93,278 patients. There was substantial heterogeneity in the meta-analyses of major cardiovascular events (19 studies, I2 = 79%) or myocardial infarction (12 studies, I2 = 77%). Analysis of propensity-matched or randomized trial participants showed no associated cardiovascular risk with PPIs, whereas other observational studies generally showed a significant association.
Thus, still today there is an emerging need for more studies, especially prospective randomized studies, to investigate the effect of individual PPI agents on clopidogrel's effectiveness. Such studies should also include a genetic component to stratify response based on the presence of reduced-function alleles of the CYP2C19 enzyme
Study Type
Enrollment (Anticipated)
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
ER
-
Ferrara, ER, Italy, 44100
- Recruiting
- University Hospital of Ferrara
-
Contact:
- Monia Monti, bSc
- Phone Number: +39 0532-236298
- Email: mntmno@unife.it
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria: All comer patients undergoing PCI will be recruited on a consecutive basis.
• Patients will undergo screening before or soon after PCI depending on their clinical presentation as follows:
- STEMI patients will receive upstream treatment with 600 mg clopidogrel before PCI and will undergo screening for 2C19 status within 24 hours after treatment. Randomization will occur immediately thereafter.
- Stable and NSTEACS patients will be treated upstream with 600 mg clopidogrel and will undergo screening either before PCI or soon after (within 6 hours) revascularisation. In both scenarios randomization will occur immediately after the genotype status is known without any additional delay.
Exclusion Criteria:
- Patients who can not give informed consent or have a life expectancy of < 1 year
- Ongoing bleeding or bleeding diathesis or increase bleeding risk or history of bleeding in the last 2 months
- Age > 90
- Previous stroke or TIA or any intracranial pathology
- Major surgery or trauma within the previous six weeks
- Platelet count < 100.000 per cubic mm or HCT ,33% or Hb < 11 gm/dL
- Subjects with an allergy or intolerance to prasugrel or to clopidogrel
- Planned elective cardiac or non-cardiac surgery within 1 month.
- Current or planned therapy with coumadin anticoagulation.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
No Intervention: no PPI
Patients, stratified according to the genetic stratum, will be randomized not to take any PPI on top of clopidogrel
|
|
Experimental: PPI
Patients stratified to the genetic stratum will be randomized to take PPI on top of clopidogrel
|
Lansoprazole 30 mg once a day
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Maximal platelet aggregation at light transmission aggregometry after 20 μmol/l ADP
Time Frame: 30 days
|
IPA expressed as maximal platelet aggregation (MPA) after 20 μmol/l ADP according to genetic stratum defined as follows: [(Poor metabolizers: 2C19*2+ and 2C19*17-); (intermediate metabolizers: wild type patients or its carrying both 2C19*2 and *170; (ultra metabolizers: 2c19*2- and 2C19*17+).
|
30 days
|
maximal platelet aggregation after 5 μmol/l ADP in PPI versus no PPI treated patients
Time Frame: 30 days
|
Patients, stratified by genetic stratum, will be randomized to PPI or no PPI.
We assume that that will be an interaction in the IPA after 5 μmol/l ADP at 30 days so that PPI will blunt responsiveness to clopidogrel in poor metabolizer patients only but in intermediate or ultra metabolizers.
|
30 days
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- GEN-2011-1
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Coronary Stenting
-
Shiraz University of Medical SciencesCompletedCoronary StentingIran, Islamic Republic of
-
Shiraz University of Medical SciencesCompletedCarotid StentingIran, Islamic Republic of
-
Sydney South West Area Health ServiceUnknownCoronary Angioplasty and Stenting | Single de Novo Coronary Artery StenosesAustralia
-
Acandis GmbHRecruiting
-
University of NebraskaNational Heart, Lung, and Blood Institute (NHLBI); National Institutes of Health...Terminated
-
Hôpital de la TimoneUnknownAcute Coronary Syndrome | Antiplatelet Therapy | Coronary StentingFrance
-
Changhai HospitalCompletedPancreatic Stenting | Pancreatic Stent DisplacementChina
-
Poitiers University HospitalCompletedNon-oncological Indication to Ureteral StentingFrance
-
Unity Health TorontoUnknownST Elevation Myocardial Infarction | Coronary Stenting | Primary Angioplasty
-
Kobe City General HospitalOsaka University; Okayama University; Kobe University; Nagoya University; Kyoto University and other collaboratorsCompletedIn-stent Restenosis After Carotid Artery StentingJapan
Clinical Trials on Lansoprazole
-
Charles Mel Wilcox, MDTakeda Pharmaceuticals North America, Inc.CompletedZollinger-Ellison Syndrome | Multiple Endocrine Neoplasia
-
Vanderbilt UniversityTAP Pharmaceutical Products Inc.Completed
-
Daewoong Pharmaceutical Co. LTD.Not yet recruitingPeptic UlcerKorea, Republic of
-
Emory UniversityUnknown
-
Daewoong Pharmaceutical Co. LTD.UnknownHealed Erosive EsophagitisKorea, Republic of
-
Il-Yang Pharm. Co., Ltd.Not yet recruitingPeptic UlcerKorea, Republic of
-
Onconic Therapeutics Inc.Not yet recruiting
-
Jordan Collaborating Cardiology GroupUniversity of JordanCompleted
-
University of UtahTerminated
-
University of Southern CaliforniaCompletedPeptic Ulcer HemorrhageUnited States